Jannah Theme License is not validated, Go to the theme options page to validate the license, You need a single license for each domain name.
USA

4/13 Thursday Insider Purchase Report: BTTX, VRDN

As the saying goes, there are many reasons an insider might sell stock, but only one reason to buy it. So let’s take a look at two of his notable recent insider purchases.

On Monday, Better Therapeutics (BTTX)’s Frank Karbe bought BTTX for $200,000 and bought 242,424 shares at $0.82 per share. Karbe is up around 81.8% on the buy highs of today’s trading session, with BTTX trading up to $1.50 on today’s final check. Better Therapeutics is up about 4.8% on Thursday. Before this latest purchase, Karbe made another purchase in the past year, at $2.09 per share he bought 104,695 shares.

And on Wednesday, CEO Scott Danses Meyers bought Viridian Therapeutics (VRDN) worth $101,479, buying 4,000 shares at $25.37 a share. Prior to this latest purchase, Myers made another purchase over the past year, at $29.15 a share he bought 160,324 shares. Viridian Therapeutics is up about 6.1% on Thursday. So far, Myers is up about 6.1% in buying and entering the green based on today’s trading volume of his $26.91.


Video: Thursday 4/13 Insider Purchase Reports: BTTX, VRDN

The views and opinions expressed herein are those of the authors and do not necessarily reflect those of Nasdaq, Inc.

Summarize this content to 100 words

As the saying goes, there are many reasons an insider might sell stock, but only one reason to buy it. So let’s take a look at two of his notable recent insider purchases.

On Monday, Better Therapeutics (BTTX)’s Frank Karbe bought BTTX for $200,000 and bought 242,424 shares at $0.82 per share. Karbe is up around 81.8% on the buy highs of today’s trading session, with BTTX trading up to $1.50 on today’s final check. Better Therapeutics is up about 4.8% on Thursday. Before this latest purchase, Karbe made another purchase in the past year, at $2.09 per share he bought 104,695 shares.

And on Wednesday, CEO Scott Danses Meyers bought Viridian Therapeutics (VRDN) worth $101,479, buying 4,000 shares at $25.37 a share. Prior to this latest purchase, Myers made another purchase over the past year, at $29.15 a share he bought 160,324 shares. Viridian Therapeutics is up about 6.1% on Thursday. So far, Myers is up about 6.1% in buying and entering the green based on today’s trading volume of his $26.91.

Video: Thursday 4/13 Insider Purchase Reports: BTTX, VRDN

The views and opinions expressed herein are those of the authors and do not necessarily reflect those of Nasdaq, Inc.

https://www.nasdaq.com/articles/thursday-4-13-insider-buying-report:-bttx-vrdn 4/13 Thursday Insider Purchase Report: BTTX, VRDN

Back to top button